Merck, KGaA, Darmstadt, Germany, Targets Emerging Markets
In an interview with Spanish daily El Pais, Belén Garijo, CEO Healthcare at Merck KGaA, Darmstadt, Germany, explains that the year 2014 was very positive for the biopharmaceuticals business as the strategic program for the years 2012 - 2018 has started to bear fruit. Even more important than the sustained growth in sales were the results of the improvement plan for Research & Development, Garijo said. Merck, KGaA, Darmstadt, Germany, focuses its healthcare research on three fields: oncology, immunology and immuno oncology. As part of its growth strategy, the business is counting on emerging markets, where more than one-third of its sales are generated. With governments being committed to providing a better health system for their citizens, Merck, KGaA, Darmstadt, Germany, focuses on a drug portfolio inteded for basic health treatment in those markets.